MetaCap

Celcuity (CELC) vs Personalis (PSNL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Personalis (PSNL) has outperformed Celcuity (CELC) over the past year, gaining 46.7% versus a loss of 45.3%. Over five years, CELC leads with a +249.6% price change compared with +2.0% for PSNL. Celcuity is the larger company by market cap ($2.61 billion vs $1.55 billion), about 1.7 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELC-45.28%PSNL+46.66%
+96%+20%-55%
Nov 21, 20251 yearNov 20, 2026
CELC+231.99%PSNL-4.55%
+803%+333%-136%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELC versus PSNL key metrics
MetricCELCPSNL
Share price$53.35$14.27
Market cap$2.61B$1.55B
1-day change-5.26%-3.06%
YTD return-46.51%+79.27%
1-year return-45.28%+46.66%
5-year return+249.61%+2.00%
EPS (TTM)$-4.72$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$69.65M
Revenue growth (YoY)—-17.69%
Net income (latest FY)$-177.04M$-81.27M
Gross margin—22.65%
Operating margin—-126.43%
Net margin—-116.69%
52-week high$151.02$18.89
52-week low$53.20$4.96
Distance from 52-week high-64.67%-24.46%
Analyst consensusstrong_buyhold
Avg. price target upside+182.76%+6.31%
Average volume1.25M2.49M
Shares outstanding48.93M108.40M
Employees155259
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PSNL has outperformed CELC by 91.9 percentage points over the past year.

About Celcuity

CELC stock →

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).

Health Care · Medical Specialities · 155 employees

About Personalis

PSNL stock →

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.

Health Care · Medical Specialities · 259 employees

CELC vs PSNL FAQ

Which is bigger, Celcuity or Personalis?

Celcuity (CELC) is larger, with a market capitalization of $2.61B compared with $1.55B for Personalis (PSNL).

Which stock has performed better over the past year, CELC or PSNL?

PSNL returned +46.66% over the past 12 months, compared with -45.28% for CELC (price return, excluding dividends). Past performance does not predict future results.

Are Celcuity and Personalis in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons